Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer that is confirmed by pathology tests, where the cancer is localised or locally advanced (has not spread far from the prostate).
- People who can speak, read, and understand Dutch, French, or English.
- People (or their legally accepted representative) who are willing to sign a consent form showing they understand the study and agree to take part.
Who may not be able to join:
- People who have previously received treatment for prostate cancer.
- People living with dementia, significant mental health conditions, or psychiatric conditions that may affect their ability to give informed consent or follow the trial requirements.
- People who are unable to follow the trial's requirements for psychological, social, family, or geographical reasons.
- People who are imprisoned or under legal guardianship.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wouter Everaerts, MD, PhD, UZ Leuven / KU Leuven
Phone: +3216346687
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assessment of systematically reporting a standardized set of predefined clinical parameters; Assessment of systematically collecting a predefined set of patient-reported outcomes
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.